Assessment of serum markers in preeclampsia: A prospective study

Abstract

Preeclampsia is a disease characterized by hypertension, proteinuria, and edema that occurs after the 20th gestational week. It is among the most important reasons for maternal/perinatal morbidity and mortality. Although many studies have been carried out, the pathophysiology of the disease is not fully known. Many methods have been proposed for evaluating risk factors leading to preeclampsia. In the past, the methods used to predict preeclampsia have usually been focused on non-biochemical markers, but nowadays there is a shift towards biochemical markers. Recently, many biochemical agents have been started to be used in the prediction of preeclampsia. In this study, the evaluation of some serum biomarkers in the follow-up preeclampsia was aimed. Serum nesfatin, ezrin, placental protein 13, hypoxia-inducible factor 1-α subunit (HIF1A), and neuropilin 1 levels were examined with the ELISA method. In the study, 90 samples taken from subjects, including pre-treatment preeclampsia (n =35), post-treatment preeclampsia (n = 35), and healthy control (n = 20) groups were evaluated. The data obtained from the study was analyzed with SPSS 22.0. As a result of the statistical analysis, pre-treatment nesfatin-1, and ezrin levels were found significantly lower than post-treatment and the healthy control group and HIF-1A levels were found significantly higher. As a result of these analyses, pre-treatment and post-treatment PP13 levels were found to be significantly higher than the healthy control group.Considering the results obtained from the study, we can say that nestin, ezrin, HIF1A, PP13, and NRP1 are important biomarkers for predicting preeclampsia.